| Name | Title | Contact Details |
|---|
STARK Group is a leading provider of building materials and services for the construction industry in Europe. Founded in 1896 and headquartered in Frederiksberg, Denmark, the company operates over 1,100 branches and distribution centers across Europe, employing around 19,000 people. STARK Group specializes in the distribution and retail of building materials to professional builders and contractors. They offer product knowledge and advice to help customers select the right materials for their projects. The company also provides efficient logistics solutions to ensure timely delivery of products to construction sites. Their extensive product portfolio includes a wide range of heavy construction materials tailored to meet the diverse needs of the construction sector. STARK Group is committed to sustainability, investing in environmentally friendly facilities and aiming for low-emission classifications in their operations.
Blue Giant Equipment Corporation is a prominent global manufacturer and distributor of loading dock systems and material handling equipment, headquartered in Toronto, Ontario, Canada. Founded in 1963 by Kurt Larsen, the company has celebrated over 60 years of innovation in the industry. Blue Giant began with mechanical dock levelers and hand pallet trucks, later expanding its offerings to include intelligent dock controls and air-powered loading dock equipment. The company provides a wide range of products, including loading dock systems, material handling equipment, HVLS fans, and ergonomic lift assist solutions. Their innovative Blue Genius Connect control panel enhances the management of loading dock operations. Blue Giant has received multiple awards for its products, including recognition in the Professional Door Dealer magazines "Best of Business Dealers Choice Poll" and a Bronze Award from Plant Engineering magazine. With a commitment to growth, Blue Giant relocated its headquarters in 2017 to a larger facility in Mississauga, Ontario, reflecting its dedication to expanding its capabilities in the material handling sector.
Progress is achieved by those with the courage to reimagine whats possible. Audi was born more than a century ago with a vision of boldly challenging the status quo and is bound by a promise to imaginatively innovate. We believe the best ideas—the ideas that will define our future—will come from new ways of thinking. We believe everyone should have a voice. We believe in equality. We believe that "we" includes all of us. For these reasons, we strive to create a workplace where diverse ideas are embraced, where people can be themselves, and where everyone comes together to reinvent mobility, drive toward a more sustainable future and create amazing customer experiences.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.